Compare ZENITH HEALTH with SYNCOM FORMULATIONS - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ZENITH HEALTH vs SYNCOM FORMULATIONS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ZENITH HEALTH SYNCOM FORMULATIONS ZENITH HEALTH/
SYNCOM FORMULATIONS
 
P/E (TTM) x 96.9 29.7 326.1% View Chart
P/BV x 5.9 4.7 126.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ZENITH HEALTH   SYNCOM FORMULATIONS
EQUITY SHARE DATA
    ZENITH HEALTH
Mar-20
SYNCOM FORMULATIONS
Mar-21
ZENITH HEALTH/
SYNCOM FORMULATIONS
5-Yr Chart
Click to enlarge
High Rs34 73.8%   
Low Rs11 120.3%   
Sales per share (Unadj.) Rs2.23.1 71.9%  
Earnings per share (Unadj.) Rs0.10.4 28.5%  
Cash flow per share (Unadj.) Rs0.20.4 36.3%  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs1.22.3 52.9%  
Shares outstanding (eoy) m53.74789.95 6.8%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x0.80.7 111.5%   
Avg P/E ratio x17.76.3 281.2%  
P/CF ratio (eoy) x12.25.5 220.8%  
Price / Book Value ratio x1.61.0 151.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m1001,833 5.5%   
No. of employees `000NANA-   
Total wages/salary Rs m9183 5.2%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m1202,448 4.9%  
Other income Rs m371 4.2%   
Total revenues Rs m1232,519 4.9%   
Gross profit Rs m5380 1.4%  
Depreciation Rs m340 6.3%   
Interest Rs m04 1.8%   
Profit before tax Rs m6407 1.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m0115 0.2%   
Profit after tax Rs m6292 1.9%  
Gross profit margin %4.615.5 29.4%  
Effective tax rate %3.328.3 11.6%   
Net profit margin %4.711.9 39.6%  
BALANCE SHEET DATA
Current assets Rs m611,996 3.1%   
Current liabilities Rs m211,065 2.0%   
Net working cap to sales %33.538.0 88.0%  
Current ratio x2.91.9 153.4%  
Inventory Days Days7100 6.8%  
Debtors Days Days31111,558,597 0.0%  
Net fixed assets Rs m211,018 2.0%   
Share capital Rs m54790 6.8%   
"Free" reserves Rs m10988 1.0%   
Net worth Rs m641,778 3.6%   
Long term debt Rs m00-   
Total assets Rs m823,014 2.7%  
Interest coverage x84.6105.4 80.3%   
Debt to equity ratio x00-  
Sales to assets ratio x1.50.8 179.2%   
Return on assets %7.09.8 70.9%  
Return on equity %8.816.4 53.9%  
Return on capital %9.223.1 40.0%  
Exports to sales %069.7 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,707 0.0%   
Imports (cif) Rs mNA4 0.0%   
Fx inflow Rs m691,707 4.1%   
Fx outflow Rs m14 37.2%   
Net fx Rs m681,704 4.0%   
CASH FLOW
From Operations Rs m20-20 -98.0%  
From Investments Rs m-5-727 0.7%  
From Financial Activity Rs mNA720 -0.0%  
Net Cashflow Rs m14-27 -52.5%  

Share Holding

Indian Promoters % 28.7 44.0 65.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.4 0.6 67.2%  
FIIs % 0.0 0.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 71.3 56.0 127.3%  
Shareholders   28,995 120,800 24.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ZENITH HEALTH With:   LINCOLN PHAR  JUBILANT PHARMOVA   CORAL LAB.  NUTRAPLUS PR  JAGSON PHAR  



Today's Market

Bloodbath on Dalal Street: 6 Reasons Why Sensex Slumped 1,688 Points Today(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended deep in the red.

Related Views on News

SYNCOM FORMULATIONS 2020-21 Annual Report Analysis (Annual Result Update)

Nov 19, 2021 | Updated on Nov 19, 2021

Here's an analysis of the annual report of SYNCOM FORMULATIONS for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of SYNCOM FORMULATIONS. Also includes updates on the valuation of SYNCOM FORMULATIONS.

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

How to Hit Rs 100 Crore Wealth in Your Lifetime(Equitymaster Wealth)

Nov 15, 2021

This is how you can achieve the ambitious goal of a net worth of Rs 100 crore.

Don't Sell these Stocks if the Market Falls(Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing.(Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ZENITH HEALTH SHARE PRICE


Nov 26, 2021 (Close)

TRACK ZENITH HEALTH

  • Track your investment in ZENITH HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ZENITH HEALTH 5-YR ANALYSIS

COMPARE ZENITH HEALTH WITH

MARKET STATS